To date, several studies have suggested that elevated Hcy could promote angiotensin-converting enzyme (ACE) activity and act synergistically with angiotensin II to cause damage to the vasculature and lead to the deterioration of endothelial function. [11] [12] [13] Moreover, higher Hcy concentrations have been shown to significantly reduce bradykinin-induced changes in BP, blood flow, and vascular resistance. 14 The main mechanisms of action of ACE inhibitors (ACEIs) include decreased formation of the vasoconstrictor angiotensin II and increased levels of the vasodilator bradykinin. While it is plausible that Hcy concentrations may affect BP and confer a modifying effect on the antihypertensive responses to ACEIs, to date, such a hypothesis has not been tested in clinical trials.
The CSPPT (China Stroke Primary Prevention Trial) compared the efficacy of a combination of the ACEI enalapril and folic acid with enalapril alone in reducing the risk of first stroke in Chinese adults with hypertension. We previously reported that folic acid therapy reduced the risk of first stroke by 21% after 4.5 years of treatment. 15 This study, a post hoc analysis of the CSPPT, examines whether baseline Hcy concentrations affect the antihypertensive responses to enalapril treatment in previously untreated hypertensive patients.
Materials and Methods
Materials and methods are available in the online-only Data Supplement. Briefly, the CSPPT was a randomized, double-blind, actively controlled trial that was conducted from May 2008 to August 2013 in 32 communities in Anhui and Jiangsu provinces of China. This study enrolled previously untreated hypertensive patients from the CSPPT.
Results
The CSPPT included a total of 10 783 subjects with untreated hypertension ( Figure I in the online-only Data Supplement). Subjects were divided into 3 groups based on their baseline Hcy concentrations (<10, 10-<15, and ≥15 μmol/L). General characteristics of these 3 groups are presented in Table 1 . Hcy concentrations were directly associated with age, male sex, smoking or drinking, methylenetetrahydrofolate reductase 677 TT genotype, creatinine, and total cholesterol and were inversely associated with body mass index, folate, and vitamin B12 concentrations. Simultaneously, Hcy concentrations were positively correlated with systolic BP (SBP; per 1 μmol/L Hcy increase: β=0.06; 95% confidence interval [CI] 0.01-0.10) and diastolic BP (DBP; per 1 μmol/L Hcy increase: β= 0.07; 95% CI 0.04-0.09) levels at baseline (Figure 1 ).
Furthermore, there was an inverse association between baseline Hcy concentrations and SBP reduction after the 3-week (per 1 μmol/L Hcy increase: β=−0.08; 95% CI −0.13 to −0.02) and the 15-week (per 1 μmol/L Hcy increase: β=−0.14; 95% CI −0.24 to −0.05) enalapril alone treatment period and the 4.5-year enalapril-based antihypertensive treatment period (per 1 μmol/L Hcy increase β=−0.03; 95% CI After the 3-week treatment period with enalapril alone (n=6876), the SBP-lowering effect was significantly reduced by 1.39 (95% CI 0.40-2.37) and 3.25 (95% CI 1.98-4.52) mm Hg in those with baseline Hcy concentrations of 10 to 15 and ≥15 μmol/L, respectively (P for trend <0.001), as compared with those with Hcy concentration of <10 μmol/L (Table 2) . Consistently, the SBP-lowering effect decreased through the quartiles of baseline Hcy concentrations (P for trend <0.001; Figure 2) .
A similar inverse association between baseline Hcy concentration and the SBP-lowering effect was observed after the 15-week enalapril alone treatment period (n=2360, a 3-week run-in treatment period, followed by a 12-week double-blind treatment period). The SBP-lowering effect was significantly reduced by 2.04 (95% CI 0.23-3.84) and 3.56 (95% CI 1.34-5.77) mm Hg in those with Hcy concentrations of 10 to 15 and ≥15 μmol/L, respectively, as compared with those with Hcy concentration of <10 μmol/L ( Table 2 ; P for trend =0.002). A weaker inverse association was also observed after the 3-week enalapril alone treatment followed by the 12-week enalaprilfolic acid treatment period (n=2478; Table I in the online-only Data Supplement).
After the median 4.5-year enalapril-based antihypertensive treatment period (n=5352), the inverse association between Hcy concentrations and SBP reduction remained significant, but was attenuated to 0.77 (95% CI 0.01-1.53) and 1.70 (95% CI 0.72-2.68) mm Hg in those with Hcy concentrations of 10 to 15 and ≥15 μmol/L, respectively, as compared with those with Hcy concentration of <10 μmol/L (P for trend <0.001; Table 2 and Figure 2 ). A weaker inverse association was also observed after the 4.5-year enalapril-folic acid-based treatment period (n=5431; Table II in the online-only Data Supplement).
Moreover, Hcy concentrations were reduced by 2.4 μmol/L in the enalapril group and 5.6 μmol/L in the enalapril-folic acid group among those with Hcy concentration of ≥15 μmol/L, increased by 1.1 μmol/L in the enalapril group and unchanged in the enalapril-folic acid group among those with Hcy concentration of 10 to 15 μmol/L, and increased by 1.7 μmol/L in the enalapril group and 1.3 μmol/L in the enalapril-folic acid group among those with Hcy concentration of <10 μmol/L (Table III in An inverse association between baseline Hcy concentration and DBP reduction was observed after the 3-week (per 1 μmol/L Hcy increase: β=−0.04; 95% CI −0.07 to −0.01) and the 15-week (per 1 μmol/L Hcy increase: β=−0.06; 95% CI −0.11 to −0.01) enalapril alone treatment period (Table 3 and Figure 2 ; Figure V in the online-only Data Supplement). However, Hcy concentrations had no significant effect on DBP reduction after the 3-week enalapril alone treatment period followed by the 12-week enalapril-folic acid treatment period ( Table I in Table 3 and Figure 2 ).
The rates of hypertension control were higher in subjects with lower baseline Hcy concentrations. The hypertension control rate was 46.2% in the Hcy concentration of <10 μmol/L group, 43.3% (compared with the Hcy concentration of <10 μmol/L; odds ratio 0.86; 95% CI 0.75-0.99) in the Hcy concentration of 10 to 15 μmol/L group, and 39.3% (compared with the Hcy concentration of <10 μmol/L; odds ratio 0.76; 95% CI 0.63-0.91) in the Hcy concentration of ≥15 μmol/L group (P for trend =0.003; Table IV in the online-only Data Supplement) after the 3-week enalapril alone treatment period. Similarly, after the 4.5-year enalapril treatment period, the rates of hypertension control were 56.4% in the Hcy concentration of <10 μmol/L group and reduced to 53.5% (compared with the Hcy concentration of <10 μmol/L; odds ratio 
Discussion
Our study served to bridge previous laboratory findings [11] [12] [13] [14] with real-world clinical translation. It is the first to demonstrate a positive association between Hcy concentration and SBP or DBP levels at baseline and to elucidate that higher baseline Hcy concentrations, even that of a moderate increase (10-15 μmol/L), are significantly associated with decreased antihypertensive response to short-or long-term enalapril-based antihypertensive treatments in previously untreated hypertensive patients. Furthermore, this association was attenuated Model 1 was adjusted for age, sex, study centers, SBP, and DBP at baseline; Model 2 was adjusted for the variables in Model 1 and total cholesterol, triglycerides, HDL cholesterol, body mass index, fasting glucose, folate, vitamin B12, creatinine, MTHFR C677T polymorphisms, smoking status, and drinking status. DBP indicates diastolic blood pressure; HDL, high-density lipoprotein; MTHFR, methylenetetrahydrofolate reductase; and SBP, systolic blood pressure.
*Systolic blood pressure (SBP) at baseline minus that after treatment. †SBP at baseline minus the time-averaged SBP during the treatment period.
with increasing follow-up time and possibly through a reduction in Hcy concentration during follow-up. These results suggest that baseline Hcy concentration may possibly be a powerful predictor for the benefit of antihypertensive therapy and a critical therapeutic target. Our findings raised the possibility that by better understanding and lowering the adverse effect of elevated Hcy on the antihypertensive therapy, we may be better able to improve BP control, which has remained to be a big challenge in clinical and community settings. Several potential mechanisms may contribute to the reduced enalapril efficacy in hypertensive patients with higher Hcy levels. A more likely mechanism by which elevated Hcy levels reduced enalapril efficacy could be the direct effect of HHcy in causing vascular dysfunction independent from renin-angiotensin system. We have demonstrated that HHcy inhibited endothelial-dependent vessel relaxation in conduit artery via protein kinase C-related endothelial nitric oxide synthase inactivation and μ-calpain activation 16, 17 and impaired endothelium-derived hyperpolarizing factor-mediated endothelium-dependent relaxations in resistant artery via small and intermediate conductance Ca
2+
-activated potassium channel inactivation. 7 These mechanisms can directly cause impaired vascular function in HHcy patients and reduce therapeutic effect of enalapril. The second potential mechanism could be related with the activation of renin-angiotensin system. A previous study 18 showed that H 2 S inhibits the ACE activity of endothelial cells. H 2 S is generated from L-cysteine and is catalyzed by either cystathionine-β synthase or cystathionine-γ lyase. The activity of cystathionine-γ lyase may be severely impaired during HHcy because of damage and precipitation of modified cystathionine-γ lyase that results in attenuated H 2 S generation. 2 Therefore, it is possible that during HHcy, reduced H 2 S promotes ACE activity that may lead to the upregulation of angiotensin II. Another study 13 suggested that increased production of endothelial Hcy and its reactive metabolites (Hcy-S-S-Hcy/Hcy-thiolactone) produces N-and S-homocysteinylation of ACE to increase its activity, resulting in the upregulation of the angiotensin II. The exact mechanism by which elevated Hcy reduces enalapril efficacy still needs to be investigated thoroughly before a conclusion can be drawn. Vascular dysfunction, such as endothelial dysfunction and vascular hypertrophy, is a hallmark of hypertension, 2 and there is much evidence to support the role of Hcy in vascular dysfunction. [5] [6] [7] 16, 17 Therefore, we speculate that elevated levels of Hcy may possibly also affect the efficacy of other antihypertensive drugs. Nevertheless, future studies are necessary to further evaluate this hypothesis.
We speculated that the reduction in Hcy by folic acid therapy may partially attenuate the modifying effect of high Hcy concentrations on the antihypertensive responses to the enalapril-based treatment. Although the results are still inconclusive, higher folate intake has been reported to be associated with a lower incidence of hypertension later in life in the general population. 19, 20 Furthermore, our data showed that a 12-week daily 0.8 mg folic acid supplementation treatment period (combined with enalapril) attenuated the adverse effect of elevated Hcy concentrations on SBP and DBP lowering (Tables 2 and  3; and Table I in and 1.17 mm Hg, respectively, in the enalapril and enalaprilfolic acid groups; Table 2 and Table II in the online-only Data Supplement). Furthermore, there was a significantly positive association between Hcy reduction and the reduction of SBP levels ( Figure IV in the online-only Data Supplement). However, we did not find a significant difference in BP reduction between treatment groups (enalapril versus enalaprilfolic acid) after the 15-week or the 4.5-year treatment period (Table VII in the online-only Data Supplement). We propose several possible explanations for this. First, in the CSPPT, the mean folate levels in the enalapril alone group also increased substantially, by ≈50%, during the course of the trial. 12 This change diminished the contrast between the treatment groups. Therefore, the observed difference in Hcy levels in the CSPPT (Table III in the online-only Data Supplement) was much lower than that of most previous studies. 21 The lower Hcy differences may not provide enough power to detect a difference in BP reduction between treatment groups. Second, unless perturbed nutritionally, Hcy concentrations change relatively little over a 5-year period. 22, 23 The elevated Hcy concentration found at diagnosis was most likely a chronic condition. Consequently, the vascular damage associated with elevated Hcy potentially occurred over a period of many years. There is no indication as to how long it would take to reverse such damage. 23 Third, previous animal studies found that long-term treatment from ACEI or angiotensin receptor blocker treatment could mitigate pathological vascular damage induced by HHcy. 13, 24 Therefore, the long-term use of ACEIs may also possibly attenuate the adverse effect of elevated Hcy concentrations and the beneficial effect of Hcy lowering on BP reduction. Overall, the association between Hcy reduction folic acid therapy and the adverse effect of elevated Hcy on the antihypertensive efficacy of enalapril still needs to be further investigated in future studies.
The higher level of Hcy (≥15 μmol/L) reduced the BP-lowering effect of enalapril on average by ≈2 to 3 mm Hg. Although this reduction seems to be small in magnitude, previous studies showed that BP bears an independent continuous relationship with the incidence of cardiovascular events. A previous meta-analysis of 61 prospective studies reported that even a 2 mm Hg decrease in SBP would reduce stroke mortality by ≈10% and would reduce mortality from ischemic heart disease or other vascular causes in middle age by ≈7%. 25 Moreover, when we analyzed hypertension control as the outcome, we found that higher level of Hcy (≥15 versus <10 μmol/L) resulted in a significant absolute reduction in the hypertension control rate by ≈7% (Table IV and V in the online-only Data Supplement). To put this number in perspective, hypertension control rate was only 9.3% in a nationally representative sample of Chinese adults in 2009-2010. 26 The strengths of our study include large sample size, different treatment periods, and comprehensive adjustments for the major associated factors. The potential limitations of the current analysis should also be considered in interpreting the study results. First, the CSPPT used a fixed dose of folic acid (0.8 mg daily). Although this is believed to be a reasonable dose, according to previous studies, to reduce Hcy concentration, 27 in our study those with Hcy concentrations ≥15 μmol/L at baseline still had significantly higher Hcy concentrations, compared with those with Hcy <10 μmol/L, after long-term folic acid supplementation. Additional research is needed to determine more useful strategies to further decrease Hcy concentrations. Second, the CSPPT used a fixed dose of enalapril (10 mg daily). We could not determine whether the modifying effect of Hcy may have changed because of the enalapril dosage or because of other ACEIs. Third, serum Hcy concentration was only assessed at the baseline and the at exit visit (after the 4.5-year treatment period). More frequent measurements of Hcy would have allowed for a more accurate assessment of the effect of Hcy reduction.
In conclusion, elevated Hcy concentrations significantly decreased the antihypertensive effect of the short-and longterm enalapril-based antihypertensive treatment in previously untreated hypertensive patients. Our findings provided new insight on the role of elevated Hcy in modifying BP control.
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